CNCE Concert Pharmaceuticals Inc.

9.38
-0.06  -1%
Previous Close 9.44
Open 9.42
Price To Book 1.32
Market Cap 220704393
Shares 23,529,253
Volume 87,275
Short Ratio
Av. Daily Volume 326,304

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 8mg data released November 12, 2018 - primary endpoint met. Presentation at WCHR, April 25, 2019 at 11am GMT. 12mg data due 3Q 2019.
CTP-543
Alopecia areata
Phase 3 first trial data noted primary endpoint met with one of the two doses. Data due from second trial December 2019.
AVP-786
Agitation in patients with Alzheimer's disease
Phase 3 planned. Needs partner
CTP-499
Diabetic Kidney Disease
Phase 1 data due 2Q 2019.
CTP-692 (single dose)
Schizophrenia
Phase 1 data due 2Q 2019.
CTP-692 (single ascending dose)
Schizophrenia
Phase 2 initiation announced March 6, 2019. To be completed 2H 2019.
CTP-543 - open label (Once-Daily vs. Twice-Daily)
Alopecia areata
Phase 1 trial initiation announced April 10, 2019 with top-line data due 2Q 2019.
CTP-692 (multiple ascending dose)
Schizophrenia

Latest News

  1. Concert Pharma Initiates Early-Stage Schizophrenia Study
  2. Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting
  3. Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia
  4. Concert Pharmaceuticals' stock takes a sharp dive after disappointing patent appeal board ruling
  5. Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding
  6. New Strong Sell Stocks for March 25th
  7. Concert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare Conference
  8. Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed
  9. Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
  10. Edited Transcript of CNCE earnings conference call or presentation 28-Feb-19 1:30pm GMT
  11. Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting
  12. Concert Pharmaceuticals, Inc. (CNCE) Q4 2018 Earnings Conference Call Transcript
  13. Concert Pharmaceuticals Reports Year Ended 2018 Financial Results and Provides Update on Clinical Programs
  14. Concert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019
  15. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Time For A Financial Health Check
  16. Analysis: Positioning to Benefit within Masco, Ascena Retail Group, Leidos, NetScout, MYR Group, and Concert Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  17. Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting
  18. Mizuho's 9 Best Biotech Stocks to Buy for 2019
  19. Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia